Klinische Onkologie 2009/2010

Mehr zum Buch

HARNBLASENKARZINOM: Hartmann (Erlangen) discusses classical and molecular pathology. Albers (Düsseldorf) focuses on function-preserving therapy for advanced cases. Roedel (Frankfurt) examines neoadjuvant radio-chemotherapy for muscle-invasive types, while Rüppen (Essen) covers chemotherapy for advanced stages. HODENTUMOREN: Albers (Düsseldorf) evaluates treatment options for high-risk non-seminoma stage I—surgery, one cycle of PEB, or monitoring. Schmidberger (Mainz) explores seminoma treatment through radiation or one to two cycles of carboplatin. Beyer (Berlin) addresses recurrence therapy in metastatic testicular cancer. PROSTATAKARZINOM: Engers (Düsseldorf) emphasizes the importance of pathological evaluation. Müller-Lisse (München) compares MR-spectroscopy, perfusion imaging, and MRI at 1.5 or 3.0 Tesla. Kotzerke (Dresden) discusses Cholin-PET/CT for PSA recurrence. Bangma (Rotterdam) presents the PRIAS study on intensive monitoring versus radical prostatectomy. Rabenalt (Düsseldorf) outlines selection criteria for radical prostatectomy, while Schwarz (Hamburg) reviews indications and morbidity associated with brachytherapy. Budach (Düsseldorf) investigates IMRT for prostate cancer, and Wiegels (Ulm) addresses adjuvant radiation therapy for R1 resections with or without hormone treatment. NIERENZELLKARZINOM: Hartmann (Erlangen) identifies new histopathological entities. Giessing (Düsseldorf) contrasts organ-preservin